Telomir Regulatory Monday, September 14, 2026 0.00 Neutral

Telomir announces in-vitro anti-cancer activity to advance osteosarcoma research

Telomir reported preclinical findings from The Ohio State University demonstrating Telomir-Zn inhibits cell growth in both human and canine osteosarcoma models, supporting parallel development pathways.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day